Ophthalmic manifestations and vision impairment in Lassa fever survivors.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2020
Historique:
received: 16 10 2020
accepted: 25 11 2020
entrez: 10 12 2020
pubmed: 11 12 2020
medline: 30 1 2021
Statut: epublish

Résumé

The purpose of this study was to describe the ocular findings, structural ocular complications, and vision impairment in a cohort of Lassa fever survivors in Kenema, Sierra Leone. A retrospective, uncontrolled, cross-sectional study of 31 Lassa fever survivors (62 eyes) who underwent an ophthalmic evaluation in January 2018 at the Kenema Government Hospital in Kenema, Sierra Leone was performed. Data collection included demographic information, ocular/systemic symptoms, visual acuity (VA), and ophthalmic examination findings. Main outcome measures included anterior and posterior segment ophthalmic manifestations and level of VA impairment in Lassa fever survivors. Anterior segment findings included cataract (18%) and pterygium (2%), while posterior segment manifestations consisted of glaucoma (6%), preretinal hemorrhage (2%), and lattice degeneration (2%). Findings suggestive of prior sequelae of uveitis included chorioretinal scarring (5%), retinal fibrosis (3%), and vitreous opacity (2%). Visual acuity was normal/mildly impaired in 53 eyes (85%), moderately impaired in 6 eyes (10%), and 3 eyes (5%) were considered blind by the World Health Organization (WHO) criteria. Median VA was worse in Lassa fever survivors with ophthalmic disease findings (p<0.0001) for both anterior segment (p<0.0001) and posterior segment disease (p<0.013). Untreated cataract was a significant cause of visual acuity impairment (p<0.0001). Lassa fever survivors in this cohort were found to have cataract and posterior segment findings that potentially represent sequelae of uveitis associated with visual impairment. Future studies are warranted to improve our understanding of the spectrum of ocular disease in this emerging infectious disease of public health consequence.

Identifiants

pubmed: 33301526
doi: 10.1371/journal.pone.0243766
pii: PONE-D-20-32591
pmc: PMC7728206
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0243766

Subventions

Organisme : NEI NIH HHS
ID : K23 EY030158
Pays : United States
Organisme : NEI NIH HHS
ID : P30 EY006360
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI123535
Pays : United States
Organisme : NEI NIH HHS
ID : R01 EY029594
Pays : United States

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Viruses. 2012 Oct 09;4(10):2031-48
pubmed: 23202452
Am J Ophthalmol. 2000 Aug;130(2):245-7
pubmed: 11004308
Br J Ophthalmol. 1994 Sep;78(9):690-3
pubmed: 7947548
Nat Rev Immunol. 2017 Mar;17(3):195-207
pubmed: 28111475
Open Forum Infect Dis. 2019 Dec 03;6(12):ofz512
pubmed: 31879673
Trans R Soc Trop Med Hyg. 1972;66(3):390-401
pubmed: 5046379
Ophthalmology. 2012 Sep;119(9):1744-53
pubmed: 22677425
PLoS Negl Trop Dis. 2018 Feb 22;12(2):e0006187
pubmed: 29470486
Emerg Infect Dis. 2019 May;25(5):865-874
pubmed: 31002065
N Engl J Med. 2015 Jun 18;372(25):2423-7
pubmed: 25950269
Ophthalmology. 2016 Dec;123(12):2626-2628.e2
pubmed: 27594198
J Cataract Refract Surg. 2004 Feb;30(2):287-90
pubmed: 15030802
J Infect Dis. 1982 Sep;146(3):360-8
pubmed: 6286795
J Infect Dis. 1987 Mar;155(3):437-44
pubmed: 3805771
J Virol. 2015 Dec 30;90(6):2920-7
pubmed: 26719273
Ocul Immunol Inflamm. 2018;26(7):1128-1134
pubmed: 29993303
Sci Rep. 2018 Apr 12;8(1):5939
pubmed: 29651117
EBioMedicine. 2018 Apr;30:217-224
pubmed: 29622497
Pediatrics. 1997 Jul;100(1):E9
pubmed: 9200383
Br J Ophthalmol. 1977 Apr;61(4):265-6
pubmed: 557985
Emerg Infect Dis. 2019 Jun;25(6):1066-1074
pubmed: 31107222
Am J Ophthalmol. 2000 Aug;130(2):209-15
pubmed: 11004296
Niger Med J. 2014 Mar;55(2):166-70
pubmed: 24791053
Ophthalmology. 2017 Feb;124(2):170-177
pubmed: 27914832
J Virol. 2009 Jan;83(1):159-66
pubmed: 18945766
Infect Dis Clin North Am. 2019 Dec;33(4):933-951
pubmed: 31668199
J Infect Dis. 1987 Mar;155(3):445-55
pubmed: 3805772

Auteurs

Alexa L Li (AL)

Section of Vitreoretinal Disease and Surgery, Department of Ophthalmology, Emory Eye Center, Emory University School of Medicine, Atlanta, Georgia, United States of America.

Donald Grant (D)

Viral Hemorrhagic Fever Program, Kenema Government Hospital, Kenema, Sierra Leone.
Ministry of Health and Sanitation, Freetown, Sierra Leone.

Michael Gbakie (M)

Viral Hemorrhagic Fever Program, Kenema Government Hospital, Kenema, Sierra Leone.

Lansana Kanneh (L)

Viral Hemorrhagic Fever Program, Kenema Government Hospital, Kenema, Sierra Leone.

Ibrahim Mustafa (I)

Viral Hemorrhagic Fever Program, Kenema Government Hospital, Kenema, Sierra Leone.

Nell Bond (N)

Department of Microbiology and Immunology, Tulane University School of Medicine, New Orleans, Louisiana, United States of America.

Emily Engel (E)

Department of Microbiology and Immunology, Tulane University School of Medicine, New Orleans, Louisiana, United States of America.

John Schieffelin (J)

Department of Pediatrics, Tulane University School of Medicine, New Orleans, Louisiana, United States of America.

Matthew J Vandy (MJ)

Ministry of Health and Sanitation, National Eye Program, Freetown, Sierra Leone.

Steven Yeh (S)

Section of Vitreoretinal Disease and Surgery, Department of Ophthalmology, Emory Eye Center, Emory University School of Medicine, Atlanta, Georgia, United States of America.

Jessica G Shantha (JG)

Section of Vitreoretinal Disease and Surgery, Department of Ophthalmology, Emory Eye Center, Emory University School of Medicine, Atlanta, Georgia, United States of America.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH